Alectinib clinical trials
Also written Alecensa, RO5424802 and RG7853.
ClinicalTrials.gov finds 100 studies for alectinib. How that becomes 59 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, to see whether and how it gives alectinib. Its counts are asked again every night. How drug pages count
- 100Found by its intervention search · See all 100 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 78 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −11
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)NCT01634763 · Earlier treatment; the study tests ceritinib after itReport a problem
- LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.NCT02450903 · Earlier treatment; the study tests ceritinib after itReport a problem
- Trial of Brigatinib After Treatment With Next-Generation ALK InhibitorsNCT02706626 · Earlier treatment; the study tests brigatinib after itReport a problem
- A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibNCT03535740 · Earlier treatment; the study tests brigatinib after itReport a problem
- Brigatinib Before Brain Irradiation Trial (B3i Trial)NCT04634110 · Excluded if taken before; the study tests brigatinibReport a problem
- Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese PatientsNCT04979988 · Earlier treatment; the study follows lorlatinib after itReport a problem
- Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLCNCT04997382 · Earlier treatment; chemotherapy and immunotherapy are tested after itReport a problem
- Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALKNCT05266846 · Earlier treatment; the study tests pembrolizumab after itReport a problem
- Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLCNCT05296278 · Earlier treatment; the study tests IBI-323 after itReport a problem
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)NCT05384626 · Earlier treatment; the study tests neladalkib after itReport a problem
- A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung CancerNCT07771764 · Later treatment if the disease grows; the study tests iruplaltinibReport a problem
- 89Give alectinib to participants
- −16Observe patients on it, or give it outside a trial
- −2Compare another treatment with it
- −12Give it beside what is tested
- 59Test it: the count on this site
Get an email when these change. Save the alectinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 11 Dec 2015 · ALECENSA · NDA 208434 (FDA, Drugs@FDA)
- European Union
- 16 Feb 2017 · Alecensa · EMEA/H/C/004164 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
59 studies that test it; most in 2021 (9)
| Year | Studies |
|---|---|
| 2013 | 6 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 7 |
| 2021 | 9 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 34
Hoffmann-La Roche (21) · Genentech, Inc. (3) · Massachusetts General Hospital (2) · China Medical University Hospital (2) · The Netherlands Cancer Institute (2) · Instituto Nacional de Cancerologia de Mexico (2) · Cancer Research UK (2) · Hunan Province Tumor Hospital (2)
Often tested with
Tested in the same studies.
Atezolizumab (16) · Entrectinib (13) · Cobimetinib (11) · Vemurafenib (10) · Trastuzumab (10) · Pertuzumab (9) · Crizotinib (7) · HhAntag691 (6)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 1 most studied
New when their studies opened, with alectinib beside them; studies of each.
Reaching primary completion within a year · 7, 3 in phase 3
Studies that test alectinib, phase 3 first.
- Nov 2026Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsPhase 2/3 · Medicine Invention Design, Inc
- Jan 2027A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Phase 3 · Hoffmann-La Roche
- Jun 2027A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Phase 2/3 · Hoffmann-La Roche
- Nov 2026A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Phase 2 · Genentech, Inc.
- Dec 2026Alectinib Pharmacokinetic in Patients With NSCLCPhase 1/2 · Instituto Nacional de Cancerologia de Mexico
- Dec 2026Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationPhase 2 · Hunan Province Tumor Hospital
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
Studies
Open first, then newest update. How each study uses alectinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 59
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245One of many approved drugs matched to tumour alterationsWritten as AlectinibReport a problem
- Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaNot yet recruitingPhase 2St. Jude Children's Research HospitalNCT07916389Before surgery in infant glioma with ALK fusionWritten as AlectinibReport a problem
- Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver MutationsNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07829744Before and after surgery, in the ALK fusion cohortReport a problem
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541One matched cohort, for ALK-altered tumoursWritten as AlectinibReport a problem
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886One arm, for ALK-positive cancersWritten as AlectinibReport a problem
- A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)RecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07001384With duvelisib in ALK-positive lymphomaWritten as AlectinibReport a problem
- Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)Not yet recruitingPhase 1/2China Medical University HospitalNCT07560410Alone in bone cancer with truncated ALKWritten as AlectinibReport a problem
- Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and ChemotherapyNot yet recruitingPhase 2Wen-zhao ZHONGNCT07573696With chemotherapy before local treatment, stage IIIReport a problem
- Alectinib Pharmacokinetic in Patients With NSCLCRecruitingPhase 1/2Instituto Nacional de Cancerologia de MexicoNCT05713006Dose escalation and blood levels in Mexican patientsWritten as Alectinib Oral ProductReport a problem
- DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive CancersRecruitingPhase 2/3Cancer Research UKNCT05770037Alone in ALK-positive cancers, adults and childrenWritten as AlectinibReport a problem
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181One of many approved drugs matched to tumour alterationsWritten as AlectinibReport a problem
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04423185One matched drug, for ALK fusion rare tumoursWritten as Alectinib 150 MGReport a problem
- Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNot yet recruitingNot applicableGuangdong Association of Clinical TrialsNCT06709274After surgery for ALK-positive patients with residual diseaseWritten as AlectinibReport a problem
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingPhase 2Hunan Province Tumor HospitalNCT04322890One ALK inhibitor for ALK fusion lung cancerWritten as Alectinib 150 MGReport a problem
- ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell CarcinomaRecruitingPhase 2Hunan Province Tumor HospitalNCT05014464One ALK inhibitor in ALK-rearranged squamous lung cancerReport a problem
- Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib BloodlevelsRecruitingPhase 4University Medical Center GroningenNCT05525338Dose raised by blood levels, against standard doseWritten as AlectinibReport a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingPhase 2Oslo University HospitalNCT04817956Off-label in one arm of a precision medicine trialReport a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234One of many approved drugs matched to tumour alterationsWritten as AlectinibReport a problem
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingPhase 2Oslo University HospitalNCT05725200One possible drug a tumour board can nominate, in colorectal cancerWritten as AlectinibReport a problem
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS TumorsActive, not recruitingPhase 1/2Hoffmann-La RocheNCT04774718Alone in children with ALK fusion tumoursWritten as AlectinibReport a problem
See all 59 studies that test alectinib →
Behind its US label · 3 — the studies the FDA label of ALECENSA describes
From the Clinical Studies section of ALECENSA (2026-08), as openFDA has it. A study the site does not hold is left out.
- A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib TreatmentCompletedPhase 1/2Hoffmann-La RocheNCT01801111Report a problem
- A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer ParticipantsCompletedPhase 3Hoffmann-La RocheNCT02075840Report a problem
- A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung CancerActive, not recruitingPhase 3Hoffmann-La RocheNCT03456076Report a problem
Tested on its own · 18 — no other medicine in its arm
- Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)Not yet recruitingPhase 1/2China Medical University HospitalNCT07560410Alone in bone cancer with truncated ALKWritten as AlectinibReport a problem
- Alectinib Pharmacokinetic in Patients With NSCLCRecruitingPhase 1/2Instituto Nacional de Cancerologia de MexicoNCT05713006Dose escalation and blood levels in Mexican patientsWritten as Alectinib Oral ProductReport a problem
- DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive CancersRecruitingPhase 2/3Cancer Research UKNCT05770037Alone in ALK-positive cancers, adults and childrenWritten as AlectinibReport a problem
- Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib BloodlevelsRecruitingPhase 4University Medical Center GroningenNCT05525338Dose raised by blood levels, against standard doseWritten as AlectinibReport a problem
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS TumorsActive, not recruitingPhase 1/2Hoffmann-La RocheNCT04774718Alone in children with ALK fusion tumoursWritten as AlectinibReport a problem
- A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung CancerActive, not recruitingPhase 3Hoffmann-La RocheNCT03456076On the US labelAgainst chemotherapy after surgery for ALK-positive lung cancerWritten as AlectnibReport a problem
- ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung CancerTerminatedPhase 2ETOP IBCSG Partners FoundationNCT03445000Alone in pretreated RET-rearranged lung cancerWritten as AlectinibReport a problem
- A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 3Hoffmann-La RocheNCT02838420Against crizotinib, first line in Asian patientsWritten as AlectinibReport a problem
- A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer ParticipantsCompletedPhase 3Hoffmann-La RocheNCT02075840On the US labelAgainst crizotinib, first line in ALK-positive lung cancerWritten as AlectinibReport a problem
- Alectinib in Neo-adjuvant Treatment of Stage III NSCLCActive, not recruitingPhase 2Gruppo Oncologico Italiano di Ricerca ClinicaNCT05015010Before and after surgery in stage III ALK-positive lung cancerWritten as AlectinibReport a problem
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedPhase 2Hoffmann-La RocheNCT04644315Alone, at home, in ALK-positive tumours other than lung cancerWritten as AlectinibReport a problem
- A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid CancerTerminatedPhase 1/2Dana-Farber Cancer InstituteNCT03131206Alone in RET-rearranged lung or thyroid cancerWritten as AlectinibReport a problem
- A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung CancerCompletedPhase 2Hoffmann-La RocheNCT03155009Alone after crizotinib in ALK-positive lung cancerWritten as AlectinibReport a problem
- Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and CrizotinibCompletedPhase 3Hoffmann-La RocheNCT02604342Against chemotherapy after crizotinib in ALK-positive lung cancerWritten as AlectinibReport a problem
- ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.Status unknownNot applicableShanghai Changzheng HospitalNCT03792568One possible ALK inhibitor in ALK-mutated colorectal cancerReport a problem
- Effect of Hepatic Impairment on the Pharmacokinetics of AlectinibCompletedPhase 1Hoffmann-La RocheNCT02621047Single dose in people with liver impairmentWritten as AlectinibReport a problem
- A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1/2Hoffmann-La RocheNCT01871805Alone after crizotinib in ALK-positive lung cancerWritten as AlectinibReport a problem
- A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802CompletedPhase 1Hoffmann-La RocheNCT01981005Single dose to trace how the body clears it, in healthy volunteersWritten as RO5424802Report a problem
Tested with established drugs · 6 — they are given beside it
- Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung CancerTerminatedPhase 1/2Massachusetts General HospitalNCT02521051With bevacizumab in ALK-positive lung cancerWritten as AlectinibReport a problem
- A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT02074553Four capsule formulations compared in healthy volunteersWritten as Ro542-4802/F03 (Reference)Report a problem
- A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib TreatmentCompletedPhase 1/2Hoffmann-La RocheNCT01801111On the US labelAlone after crizotinib in ALK-positive lung cancerWritten as AlectinibReport a problem
- A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802CompletedPhase 1Hoffmann-La RocheNCT01940510Single dose with and without rifampin in healthy volunteersWritten as RO5424802Report a problem
- A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01984229Single dose with and without posaconazole in healthy volunteersWritten as AlectinibReport a problem
- A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.CompletedPhase 1Hoffmann-La RocheNCT02023125Single dose fasted, fed and with esomeprazole in healthy volunteersWritten as AlectinibReport a problem
Tested in a combination · 32 — another drug in the study is under test too
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245One of many approved drugs matched to tumour alterationsWritten as AlectinibReport a problem
- Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaNot yet recruitingPhase 2St. Jude Children's Research HospitalNCT07916389Before surgery in infant glioma with ALK fusionWritten as AlectinibReport a problem
- Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver MutationsNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07829744Before and after surgery, in the ALK fusion cohortReport a problem
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541One matched cohort, for ALK-altered tumoursWritten as AlectinibReport a problem
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886One arm, for ALK-positive cancersWritten as AlectinibReport a problem
- A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)RecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07001384With duvelisib in ALK-positive lymphomaWritten as AlectinibReport a problem
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181One of many approved drugs matched to tumour alterationsWritten as AlectinibReport a problem
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04423185One matched drug, for ALK fusion rare tumoursWritten as Alectinib 150 MGReport a problem
- Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNot yet recruitingNot applicableGuangdong Association of Clinical TrialsNCT06709274After surgery for ALK-positive patients with residual diseaseWritten as AlectinibReport a problem
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingPhase 2Hunan Province Tumor HospitalNCT04322890One ALK inhibitor for ALK fusion lung cancerWritten as Alectinib 150 MGReport a problem
- ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell CarcinomaRecruitingPhase 2Hunan Province Tumor HospitalNCT05014464One ALK inhibitor in ALK-rearranged squamous lung cancerReport a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingPhase 2Oslo University HospitalNCT04817956Off-label in one arm of a precision medicine trialReport a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234One of many approved drugs matched to tumour alterationsWritten as AlectinibReport a problem
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingPhase 2Oslo University HospitalNCT05725200One possible drug a tumour board can nominate, in colorectal cancerWritten as AlectinibReport a problem
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2Genentech, Inc.NCT04302025Before surgery for ALK-positive lung cancerWritten as AlectinibReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 3Hoffmann-La RocheNCT05170204Against durvalumab after chemoradiotherapy, ALK-positive stage IIIWritten as AlectinibReport a problem
- A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerCompletedPhase 3Hoffmann-La RocheNCT03194893Continued for people still benefiting from earlier studiesWritten as AlectinibReport a problem
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845One cohort, for ALK fusion tumours outside the lungWritten as AlectinibReport a problem
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2/3Hoffmann-La RocheNCT03178552One cohort, for ALK- or RET-positive lung cancerWritten as AlectinibReport a problem
- A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 3Hoffmann-La RocheNCT06624059With chemotherapy after surgery for ALK-positive lung cancerWritten as AlectinibReport a problem
Showing 20 of 32. See all 32 →
Beside an established treatment under test · 2 — an approved drug, surgery or radiation is what the study tests
Tested with alectinib: Radiation 2
- Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangementsRecruitingPhase 1/2Joshua PalmerNCT05987644In every armGiven in every arm; the study tests when to give radiosurgeryWritten as AlectinibReport a problem
- Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)RecruitingNot applicableKarolinska University HospitalNCT05724004In every armFirst-line treatment, with radiotherapy added to every lesionReport a problem
Beside a new treatment under test · 2 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with alectinib: datopotamab deruxtecan 1
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingPhase 3Hoffmann-La RocheNCT03768063Continued with atezolizumab, as in the earlier studyWritten as AlectinibReport a problem
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingPhase 2AstraZenecaNCT03944772Added to osimertinib in one module after osimertinibWritten as AlectinibReport a problem
Beside supportive care · 3 — a supportive treatment or test is studied
- TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-SamplingNot yet recruitingNot applicableKarolinska InstitutetNCT07823725Usual treatment; its levels measured from finger-prick samplesReport a problem
- Personalized DC Vaccines in Non Small Cell Lung CancerActive, not recruitingPhase 1Centre Hospitalier Universitaire VaudoisNCT05195619Taken as usual care beside the vaccine, in one cohortReport a problem
- Brazilian Lung Immunotherapy StudyCompletedPhase 2Hospital Israelita Albert EinsteinNCT05081674First line for ALK-positive disease in a cost studyWritten as AlectinibReport a problem
One option of several · 5 — a test or a strategy chooses among drugs
- OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic TherapyRecruitingPhase 1M.D. Anderson Cancer CenterNCT07655583One brain-active drug given instead of radiosurgery after surgeryReport a problem
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491One drug the organoid test can chooseWritten as AlectinibReport a problem
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedPhase 2Hoffmann-La RocheNCT03498521One matched option in the targeted arm, against chemotherapyWritten as AlectinibReport a problem
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431One option in the tailored-therapy arm, against standard careWritten as AlectinibReport a problem
- Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal MetastasisStatus unknownPhase 4Hui BuNCT04356118One possible targeted drug beside endostatinReport a problem
As the comparator · 2 — what is tested is compared with alectinib
- Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCRecruitingPhase 3Nuvalent Inc.NCT06765109The comparator, against neladalkib, first lineWritten as AlectinibReport a problem
- A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung CancerCompletedPhase 3TakedaNCT03596866The comparator, against brigatinibWritten as AlectinibReport a problem
Observed · 16 — patients on it are followed, or it is given outside a trial
- Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyRecruitingHoffmann-La RocheNCT06862869After surgery in routine practice in ChinaWritten as AlectinibReport a problem
- Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell CarcinomaRecruitingFirst People's Hospital of HangzhouNCT07207278First-line ALK inhibitor in signet ring lung cancerReport a problem
- The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in ChinaNot yet recruitingShanghai East HospitalNCT06586801First-line ALK inhibitor; patient-reported outcomes followedReport a problem
- ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerRecruitingFondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06532149One of the treatments; sexual health observedWritten as AlectinibReport a problem
- Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)RecruitingFondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06234579Taken first line; resistance followed with repeat biopsiesReport a problem
- Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer PatientsEnrolling by invitationAarhus University HospitalNCT04708639Treatment followed with serial blood tests for ALKWritten as AlectinibReport a problem
- An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With AlectinibActive, not recruitingHoffmann-La RocheNCT04764188Prescribed in practice; outcomes followedWritten as AlectinibReport a problem
- KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors IIActive, not recruitingSeoul National University Bundang HospitalNCT05525858One matched drug in a molecular profiling programmeWritten as AlectinibReport a problem
- A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.CompletedPfizerNCT05834348One of many lung cancer drugs in Norwegian practiceWritten as alectinibReport a problem
- Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment PatternsCompletedPfizerNCT04351334Treatment after alectinib, looked at in practiceWritten as AlectinibReport a problem
- A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) InhibitorsCompletedTakedaNCT03546894One ALK inhibitor compared with brigatinib in practiceWritten as AlectinibReport a problem
- Alectinib-induced Endocrine ToxicityCompletedFondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06339554First-line treatment; hormone side effects observedWritten as Alectinib 150 MG [Alecensa]Report a problem
- Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.CompletedPfizerNCT04647110One ALK inhibitor in the Swedish registers' treatment sequencesWritten as alectinibReport a problem
- Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in KoreaCompletedHoffmann-La RocheNCT03271554Prescribed in Korea; side effects recordedWritten as AlectinibReport a problem
- PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort StudyStatus unknownSungkyunkwan UniversityNCT04115410Among the drugs in the chemotherapy comparison groupReport a problem
- Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor TherapyNo longer availableGenentech, Inc.NCT02271139Expanded access after another ALK inhibitorWritten as AlectinibReport a problem
What changed recently
From the registry's own updates since Oct 19, 2026.
Newly registered1
- Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaNov 4, 2026NCT07916389
Codes
What other systems call alectinib · ClinicalTrials.gg INT006325
- MeSH (NLM) C582670alectinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) LIJ4CT1Z3YALECTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1727455Confirmed FDA, Wikidata
- Wikidata Q21099132alectinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C101790AlectinibOne source FDA
- DrugBank DB11363One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C582670 | alectinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | LIJ4CT1Z3Y | ALECTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1727455 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21099132 | alectinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C101790 | Alectinib | One source FDA |
| DrugBank | DB11363 | — | One source Wikidata |
Also registered as alectinib hydrochloride (UNII P9YY73LO6J · RxNorm 1727454).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.